Integrated BioPharma, Inc. — Cyborg Score 4/10

Mixed
Nutraceutical contract manufacturing

Strategic Profile

The company operates through two segments, Contract Manufacturing that manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers, and Other Nutraceutical Businesses that provides warehousing and fulfilment services and distributes raw materials. INBP is a leader for many years in providing nutritional supplement products and services with a solid business base, long standing industry reputation and experienced management team.

Cyborg Score Rationale

INBP demonstrates steady revenue growth (8% in FY2025) and has been operational since 1980 with established industry reputation. However, the company remains small-cap (market cap ~$5.4M as of June 2026) with limited public visibility, trading OTC rather than on major exchanges. Earnings volatility and OTC status reflect execution challenges typical of micro-cap manufacturing firms.

Top Insights

  • Dual-segment model provides diversification: contract manufacturing generates stable B2B revenue while direct-to-consumer and distribution channels offer upside
  • Recent profitability recovery: FY2025 earnings of $808K represent 621% increase over prior year, signaling operational improvements
  • US-manufactured positioning aligns with consumer preference for domestic supplement sourcing in competitive nutraceutical market
  • OTC trading and $5.4M market cap indicate limited institutional investor interest and potential capital constraints for growth investments

Named Competitors

  • Vitamin and supplement contract manufacturing — Integrated nutraceutical manufacturer and distributor
  • Nutritional supplement distribution — Large-scale supplement distributor
  • Contract vitamin manufacturing — Contract manufacturer of vitamins and supplements

Recent Developments

  • (February 2026) Reported Q3 FY2026 financial results (quarter ended December 31, 2025) with continued revenue tracking
  • (FY2025 ended June 2025) Revenue increased 8% to $54.35 million with earnings up 621% to $808,000

Open the full interactive Integrated BioPharma, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →